Jubilant Life Sciences Ltd, an integrated global pharmaceuticals company, has received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (FDA) for zolmitriptan orally disintegrating tablets, 2.5 mg and 5 mg the generic version of Zomig-ZMT (AstraZeneca), which is used for acute treatment of migraine headaches in adults.
Jubilant Life Sciences had a total of 815 filings for formulations of which 389 have been approved in various regions globally as on June 30, 2015,. This includes 72 ANDAs filed in the US, of which 38 have been approved and 46 dossier filings in Europe.
Subscribe to PharmaTutor News Alerts by Email >>
